Antipyretic

Phase 2Small molecule

Ultragenyx

Antipyretic is one of 7 small molecule programs targeting Recurrent Medulloblastoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent MedulloblastomaActive, not recruiting

Recurrent MedulloblastomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Recurrent Medulloblastoma

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Phase 2

1 2

Avastin

Roche

Phase 2

1 3

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 4

Triostat

VViking Therapeutics, Inc.

Phase 2

1 5

Decadron

AAspen Global Incorporated

Phase 2

1 6

Antihistamine

Arrowhead Pharmaceuticals

Phase 2

1 7

Antipyretic

Ultragenyx

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Recurrent Medulloblastoma

NCT04743661

Clinical

Trials by Indication[1]

Glycogen Storage Disease Type II1 trial

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

Terminated· Ultragenyx logo

Ultragenyx·Phase 1/2·NCT04990388·9 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients

Completed·CCinnagen·Phase 3·NCT06406153·12 enrolled

Recurrent Medulloblastoma1 trial

Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma

Active, not recruiting·PPediatric Brain Tumor Consortium·Phase 2·NCT04743661·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Antipyretic. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antipyretic compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antipyretic. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ultragenyx company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Ultragenyx

Antipyretic

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Glycogen Storage Disease Type II1 trial

Efficacy and Safety1 trial

Recurrent Medulloblastoma1 trial

References

Drug Info

Quick Facts

Related News